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Background: Two commercially available TDP43 antibodies (phosphorylated or pTDP43, non-phosphorylated or
iTDP43) are currently in use for the neuropathological classification of FTLD-TDP cases into pathological subtypes.
To date, no studies have performed direct comparisons between these TDP43 antibodies to determine if they
identify the same FTLD-TDP subtypes. The reliability of subtype classification with the use of either of these
antibodies has also not been investigated. The present study compares the severity of pathological lesions
identified with pTDP43 and iTDP43 in a cohort of 14 FTLD-TDP cases, and assesses the accuracy and inter-observer
reliability found with either of these antibodies.
Results: pTDP43 identified a greater severity of pathological inclusions across FTLD-TDP cases in comparison to
iTDP43 and a higher inter-observer of subtype classification was found with this antibody.
Conclusion: This study demonstrates a higher consistency across independent observers in the pathological
subtyping of FTLD-TDP cases with the use of a pTDP43 antibody in comparison to the iTDP43 antibody, and
corroborates the use of pTDP43 for pathological classification of FTLD-TDP cases.
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TAR DNA Binding protein 43 (TDP43) is a normally oc-
curring nuclear protein that binds RNA and DNA and
plays a number of roles in transcription, RNA splicing
and translational regulation [1]. The presence of abnormal
TDP43 protein deposition is a pathological feature of
motor neuron disease (MND) and frontotemporal lobar
degeneration with TDP43-positive inclusions (FTLD-
TDP) and a variety of FTLD-TDP subtypes are recognized
based on the morphology and anatomical distribution of
both neuronal inclusions and dystrophic neurites [2-4]
(Figure 1). FTLD-TDP cases with moderate to numerous
TDP43-immunoreactive neuronal cytoplasmic inclusions
(NCIs) and short dystrophic neurites (DN) predominantly* Correspondence: g.halliday@neura.edu.au
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reproduction in any medium, provided the orin the upper cortical layers II/III are designated type A
(Figure 1A); cases with moderate to numerous TDP43-
immunoreactive NCIs and sparse DNs across all cortical
layers are designated type B (Figure 1B); cases in which
long dystrophic neurites are present predominantly in
the upper cortices and NCIs are rare are assigned a type
C (Figure 1C); while cases with numerous neuronal
intranuclear inclusions and DNs not restricted to any
cortical layer are assigned a type D (Figure 1D) [3].
There are, at present, two types of commercially avail-
able TDP43 antibodies used to neuropathologically iden-
tify and classify the abnormal inclusions and neurites
into the different FTLD-TDP subtypes – phosphorylated
(pTDP43) and non-phosphorylated (iTDP43) TDP43 anti-
bodies. Prior to the recent generation of pTDP43 antibody
[5], iTDP43 antibodies were mainly used for this purpose
with some debate on the necessity for TDP43 phosphoryl-
ation in disease pathogenesis (see [6] for a review). At
present there is no consensus on the use of these different. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 An illustration of the harmonized classification system used for FTLD-TDP subtyping [3]. Cases with moderate to numerous
TDP43-immunoreactive NCI and short DN predominantly in the upper cortical layers II/III were assigned a type A; cases with moderate to
numerous TDP43 immunoreactive NCIs and sparse DNs across all cortical layers were assigned a type B; cases in which long dystrophic neurites
were present predominantly in the upper cortices and NCIs were assigned a type C; cases with numerous lentiform NII were assigned a type D.
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considerable differences are observed in clinicopatholo-
gical association studies [14], possibly due to differences
in the antibody detection method used. For example,
Armstrong and colleagues [15] demonstrated an absenceFigure 2 Typical examples of TDP43-immunoreactivity with pTDP43 a
in normal neurons (A). Typical examples of pTDP43-immunoreactive pre-in
sections with iTDP43, normal neurons demonstrate TDP43 nuclear staining
(F) or NIIs (H). iTDP43-immunoreactive long DN (J, inset: short DN). Scale inof distinct subtypes using iTDP43 and later went on to re-
port that a greater number of pathological inclusions
could be identified with pTDP43 [16], which is likely to
influence the numbers and types of cases in different
FTLD-TDP subtypes. To date there have been no directnd iTDP43. In sections with pTDP43, nuclear staining is not observed
clusions (C), NCI (E), NII (G), and long DN (I, inset: short DN). In
(B) and the loss of nuclear staining (D) is often accompanied by NCIs
H (equivalent for A-G), Scale in J (equivalent for I).
Figure 3 Laminar distribution of pathological TDP43 lesions in sections of the same cases immunostained with pTDP43 (A, C, E) and
iTDP43 (B, D, F). The predominance of pathological lesions in the upper cortical layers in a case with TDP subtype A (Patient #7) was easily
visualized with pTDP43 (A) but not with iTDP43 (B). The presence of pathological lesions across all cortical layers in a case with TDP subtype B
(Patient #10) was also obvious on sections with pTDP43 (C) but not on sections with iTDP43 (D). Insets (scale=50 μm) on sections
immunostained with pTDP43 (A, C) show NCIs and DNs in the upper layers of a TDP type A case (A) and in both the upper and lower layers in a
TDP type B case (C). Insets (scale=50 μm) on sections immunostained with iTDP43 (B, D) demonstrate the broad pathological overlap observed
in cases with subtypes A and B – NCIs are observed in the deeper layers in a TDP type A case (B) but not in a TDP type B case (D). While the
distinctive long dystrophic neurites characteristic of a case with TDP type C (Patient #13) is obvious with both antibodies, its predominance in
upper cortical layers is obvious with pTDP43 (E) in comparison to iTDP43 (F, arrows).
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mine if they identify the same FTLD-TDP subtypes, par-
ticularly in C9ORF72-linked cases which are associated
with added pathological heterogeneity [17,18]. The reli-
ability of subtype classification with the use of either of
these antibodies has also not been investigated. Thepresent study aimed to compare the severity of patho-
logical lesions identified with two of the most commonly
used pTDP43 and iTDP43 antibodies in a cohort of 14
FTLD-TDP cases, and to assess the accuracy and inter-
observer reliability of these antibodies for the purpose of
FTLD-TDP subtyping.
Table 1 Inter-observer agreement for subtyping each




TDP type A cases 74% 66%
TDP type B cases 90% 55%
TDP type C cases 93% 80%
Percentages are based on five independent ratings.
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Reliability of subtyping using pTDP43
Typical examples of the pTDP43-immunoreactive lesion
pathologies are shown in Figure 2. The NCIs (Figure 2E)
were rounded in shape, the NIIs (Figure 2G) lenticular
or spindle-shaped, and the DNs were long and contorted
or short (Figure 2I). In all cases examined, lesions were
present in all cortical layers with a higher density of
pathology obvious in the upper cortices of cases with
subtypes A and C (Figure 3A, E). Five independent ob-
servers blind to case details determined the subtype for
each case with substantial agreement (κ = 0.76). Inter-
observer percentage agreement scores demonstrate diffi-
culties were mostly in cases with subtype A (Table 1). In
two cases (cases #2 and #6), a greater proportion of DNs
were observed in comparison to NCIs and although long
DNs were not present, a proportion of observers incor-
rectly classified these cases with subtype C. In another
case (case #7), moderate short DNs were observed in the
upper cortices whereas mild NCIs were found in all
cortical layers, resulting in two observers incorrectly
assigning this case a subtype B.
Reliability of subtyping using iTDP43
Typical examples of the iTDP43-immunoreactive lesion
pathologies are shown in Figure 2. Nuclei staining were ob-
served in normal cells (Figure 2B). Pathological inclusions
in the form of rounded NCIs (Figure 2F) and spindle-
shaped NIIs (Figure 2H) usually accompanied the loss of
nuclei staining in cells. Dystrophic neurites observed were
long and contorted or short (Figure 2J). The laminar distri-
bution of pathology was difficult to observe at low magnifi-
cation due to the presence of nuclei staining in normal
neurons, and remained difficult at higher magnifications
(Figure 3B, D, F), particularly in cases with sparse path-
ology. Five independent observers blind to case details de-
termined the subtype for each case with only moderate
agreement using this stain (κ = 0.42). Inter-observer per-
centage agreement scores demonstrate difficulties in cases
with subtypes A and B (Table 1). The difficulties described
above with pTDP43 (cases #2, #6, #7) were also present
with iTDP43, but observers noted less pathology in the
iTDP43-stained sections, resulting in a larger proportion ofobservers incorrectly subtyping these cases. In addition to
difficulties with subtype A cases, pathological lesions with
iTDP43 in case #1 were very scarce and could not be
subtyped by several observers. In cases #8, #9, #10 and #11
examined with iTDP43, NCIs were rare, and similar sever-
ities of DNs were seen in comparison. This resulted in a
large proportion of observers assigning these TDP type B
cases to subtype A.
Comparison of pathological inclusions identified with
pTDP43 and iTDP43
Direct comparison between subtype classification with
pTDP43 and iTDP43 showed only moderate agreement
(κ = 0.58). The assessment of similar regions in the same
sections of cases examined with pTDP43 and iTDP43
antibodies at high resolution is shown in Figure 4.
Across all cases examined, more NCIs were identified in
the cortices and dentate gyrus with pTDP43 compared
to iTDP43 (Figure 4A-H). While the absence of TDP43
nuclear staining was observed in some neurons exam-
ined with iTDP43, no concomitant pathological TDP43
inclusions were present (Figure 4G, H white arrows). The
finding of fewer pathological inclusions with iTDP43 is
unlikely to be due to oversight, as all five observers took
twice as long to examine these sections due to the staining
of many normal structures. NCIs were identified in the
dentate gyrus in all cases examined with pTDP43
(Figure 4C, F) but were absent from two cases examined
with iTDP43, one of which demonstrated a loss of nuclear
staining in surrounding neurons (Figure 4H). NIIs were
sparse and observed in the cortices of four cases with
pTDP43 (Figure 4I) but were identified in only one case
with iTDP43 (4J). Dystrophic neurites were easily identi-
fied with both antibodies, with observers reporting similar
severities in sections examined.
Comparison of the distribution of pathology identified
with pTDP43 and iTDP43
Direct comparisons of the distribution of pathology in
FTLD-TDP cases on sections of the same cases immuno-
labelled with pTDP43 and iTDP43 are shown in Figure 3.
Due to the absence of normal physiological nuclei staining
with antibodies to pTDP43, pathological lesions were more
obvious and as such, the distribution of TDP43 immunore-
active lesions in the cortices was easily visualised at low
magnification (Figure 3A, C, E). This was not the case in
sections with iTDP43 (Figure 3B, D, F). At higher magnifi-
cations (Figure 3 insets), the distribution of pathological le-
sions with iTDP43 in certain cases remained difficult and
the most obvious reason for this being the lower patho-
logical load observed with this type of antibody, making
the predominant layers involved difficult to distinguish.
Since the distinctive long dystrophic neurites characteristic
of FTLD-TDP type C are easily visualized with either
Figure 4 Pathological inclusions identified in similar sections of the same cases examined with pTDP43 and iTDP43. NCIs were observed
in the cortex on sections with pTDP43 (A), but not in the same region of sections with iTDP43 (B) in Patient #8. Moderate NCIs were observed in
the dentate gyrus on sections with pTDP43 (C) whereas only mild NCIs were observed in the same region on sections with iTDP43 (D, arrows) in
Patient #10. Compared to the NCIs observed in the upper cortices in Patient #6 with pTDP43 (E, black arrows), iTDP43 sections demonstrated less
NCIs (G, black arrows) and a loss of TDP43 nuclear staining in surrounding neurons (G, white arrows). In Patient #1, NCIs were identified in the
dentate gyrus in a case examined with pTDP43 (F), but not in sections with iTDP43 (H) although this antibody demonstrated mild loss of nuclear
staining in surrounding neurons (white arrows). NIIs were observed in the cortices of four cases (Patients #1, 3, 4, 5) with pTDP43 (I) but were
identified only in one case (Patient #1) with iTDP43 (J). Scale in A (equivalent for B,C,D,E,F,I and J), Scale in G (equivalent for H).
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the laminar pattern of lesion pathology (Figure 3E and F).
The distinction between subtypes A and B, however, is less
straightforward, particularly with iTDP43. Since less patho-
logical inclusions are identified with this antibody, there is
a greater reliance on the laminar distribution to determine
these subtypes. In cases examined with iTDP43, the pres-
ence of NCIs in the deeper layers of cases with subtypes A
(Figure 3B), and its presence in the upper layers whilstbeing absent from the deeper layers in cases with subtype
B (Figure 3D) contradicts the classification variables that
distinguish between these subtypes, with broad patho-
logical overlap for these subtypes using the iTDP43 anti-
body, as reported by others [15].
Based on the severity and distribution of pathological le-
sions identified, the five observers independently assigned
cases to FTLD-TDP subtypes. Overall, a higher inter-
observer agreement was found with typing sections
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subtypes (Table 1). Difficulties in classifying cases with
iTDP43 appear to be due to the lower pathological load
and the lack of an obvious cortical distribution of patho-
logical lesions with this type of antibody, a major factor
that enables the distinction between subtypes, particularly
in cases where pathology is sparse.
Discussion
This is the first study to carry out a comparison of inter-
observer subtyping of TDP43 pathology using antibodies
against pTDP43 and iTDP43 in the frontotemporal cor-
tices of FTLD-TDP cases. We report here a greater
inter-observer agreement with pTDP43 in comparison
to iTDP43, and only a moderate agreement between the
two antibodies. Direct comparisons of similar regions in
the same sections of cases examined with pTDP43 and
iTDP43 demonstrated more pathological inclusions with
pTDP43, as well as a clearer distribution of these in the
cortical sections. Overall, inter-observer reliability scores
demonstrated a higher reliability and consistency in the
subtyping of cases using antibodies to pTDP43.
The classification of FTLD-TDP cases into patho-
logical subgroups is weighted on the relative severities of
pathological lesions and laminar distribution of these in
the cortical layers [3]. The criterion defining these sub-
groups was developed originally with ubiquitin immuno-
histochemistry, and while successfully applied to some
FTLD-TDP cases, it has not been as easily recognized in
a large proportion of others, most probably due to theTable 2 Demographics, clinical syndrome and pathological su
cases in this study
Subtype Case # Age at death (y)/
Gender (M/F)
Disease duration (y) Ini
A 1 76F 2
A 2 84F 8 L
A 3 54F 6
A 4 60M 3 Lang
A 5* 72M 9
A 6* 65M 2
A 7* 65F 3 b
B 8* 55M 3
B 9 52F 1 b
B 10 66M 2 b
B 11 55F 2 b
C 12 68F 1 Lang
C 13 68M 12
C 14 83F 13 L
* C9ORF72 gene mutation; bvFTD behavioral frontotemporal dementia; MND motoadditional pathology identified by using TDP43 immu-
nohistochemistry [8]. In the present study, we describe
further the difficulties involved in distinguishing between
TDP subtypes A and B using an iTDP43 antibody. The
pathological overlap between these two subtypes has
been reported previously using an iTDP43 antibody [15],
and we can confirm the pathological variables that
underscore these observations. The lack of obvious cor-
tical distribution of pathology largely contributed to
these difficulties, particularly in cases where NCIs were
rare. In comparison to using an iTDP43 antibody, both
the laminar distribution of pathology and presence of
cytoplasmic inclusions were more easily identified by all
observers on sections stained with a pTDP43 antibody.
The distinctive long dystrophic neurites characteristic of
TDP type C was apparent in most instances and as such,
the lack of obvious laminar patterns of pathology found
with an antibody to iTDP43 did not affect the identifica-
tion of this subtype. Overall, we found the inter-observer
reliability scores to be higher when using a pTDP43 anti-
body, suggesting better consistency between the patho-
logical lesions identified with this antibody and the
current variables that define the subgroups.
While there is much debate at present with regards to
phosphorylation in the process of TDP43 pathology, it
has been widely accepted that the reduction in nuclear
staining, as observed with an iTDP43 antibody, precedes
the formation of pathological inclusion bodies (see [6] for
a review). The present study notes in sections examined
with an iTDP43 antibody, the lack of nuclear staining inbtypes assigned by 5 independent raters to FTLD-TDP
tial syndromes pTDP43 iTDP43
Reviewer Reviewer
1 2 3 4 5 1 2 3 4 5
bvFTD A A A A B B A A B B
anguage FTD C A A C C A A A C A
bvFTD A A A B A A A A A A
uage FTD+bvFTD A A A A A A A A A A
bvFTD A A A A A A A A C A
bvFTD A C A C A A C C B A
vFTD + MND B A B A A B A B B B
bvFTD B B B B B B B D C B
vFTD + MND B B B A B A B B A B
vFTD + MND B B B B B A B C C B
vFTD + MND B B B B B B B C B B
uage FTD + MND B C C C C B C B B C
bvFTD C C C C C C C C C C
anguage FTD C C C C C C C C C C
r neuron disease.
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TDP43 inclusions. Together with the greater severities of
inclusion bodies noted in corresponding sections with a
pTDP43 antibody, this would appear to support the
findings of Hasegawa and colleagues [8], demonstrating
that phosphorylated TDP43 is a major component of
inclusion bodies.
Of note, however, are previous reports of pTDP43
labelling intraneuronal dot-like structures that show
morphologic characters consistent with granulovacuolar
degeneration (GVD) [19], as well as partially co-localising
with pathological tau inclusions in Alzheimer’s disease
[20]. As such, while a higher accuracy in subtype classifi-
cation may be found with pTDP43, iTDP43 may demon-
strate higher specificity for FTLD pathologies.
Conclusion
In summary, this study demonstrates a higher con-
sistency across independent observers in the patho-
logical subtyping of FTLD-TDP cases with the use of a
pTDP43 antibody compared with an iTDP43 antibody.
An added advantage of this antibody is that unlike the
iTDP43 antibody, pTDP43 antibodies do not label nor-
mal physiological TDP43 in the nucleus, thereby mak-
ing it easier and consequently less time-intensive to
identify pathological lesions present in both the nucleus
and cytoplasm of neurons, and the laminar distribution
of these pathologies. Overall, the present findings cor-
roborate the use of pTDP43 antibodies in pathological
subtyping of FTLD-TDP. The higher inter-observer
consistency found with this antibody will improve the
strength of associations found in future clinicopatho-




Fourteen cases of FTLD-TDP (6 male, 8 female, see
Table 2) were selected from a clinicopathological case
series collected by the Sydney Brain Bank through a
regional brain donor program in Sydney, Australia. Ten
relatively typical cases of TDP subtypes A, B and C as
well as 4 cases with the C9ORF72 gene mutation were
selected for this study. The program holds approval from
the Human Ethics Committee of South Eastern Sydney
and Illawarra Area Health Service and The University of
New South Wales and complies with the statement on
human experimentation issued by the National Health
and Medical Research Council of Australia. All cases
were free from coexisting neuropathologies. Diagnostic
genetic [21] and neuropathological [22] screening of these
cases had been conducted previously and FTLD-TDP
cases previously subtyped as A (N=7, 3 with C9ORF72
gene expansions), B (N=4, 1 with C9ORF72 geneexpansion) or C (N=3, without C9ORF72 gene expan-
sions). FTLD-TDP subtype D is very rare and was not rep-
resented here nor in previous large clinicopathological
studies [2,11-13].
Immunohistochemistry
Paraffin sections of 10 μm thickness were taken from
the superior frontal and entorhinal cortices and hippo-
campus at the level of the lateral geniculate body.
Immunoperoxidase staining with antibodies against
pTDP43 (S409/410) (1:80,000, TIP-PTD-M01, Cosmo
Bio, Tokyo Japan) was performed using the Discovery
XT autostainer (Ventana Medical Systems). iTDP43
protein was visualised following microwave antigen re-
trieval (sections were boiled for 3 min in 0.2 M citrate
buffer, pH 6.0) using TDP43 against amino acids 1–260
(1:1000; 10782-2-AP, ProteinTech Inc., Chicago, IL),
peroxidase visualisation and counterstaining with 0.5%
cresyl violet as described previously [23].
Semiquantitative analysis of TDP43
immunohistochemistry
The cases were assessed by 5 experienced raters who
assigned the cases to the FTLD-TDP subtypes using
the recently updated classification system for FTLD-
TDP pathology [3]. In each cortical region examined,
abnormal TDP43-immunoreactivity was scored using
semi-quantitative scoring (0 = none; + = mild; ++ =
moderate; +++ = severe) [24] along strips of frontal
and entorhinal cortices parallel to the pial surface, and
also in the hippocampal dentate gyrus. The density of
neuronal cytoplasmic inclusions (NCI) (Figure 2E, F),
neuronal intranuclear inclusions (NII) (Figure 2G, H)
and dystrophic neurites (DN) (Figure 2I, J) were scored
separately, and for iTDP43 the absence of normal
nuclear staining was also scored (Figure 2D). The dis-
tribution of pathological lesions in the cortices was
also recorded (all = present in all layers; upper = re-
stricted to upper cortices; all + upper = present in all
layers with a predisposition for upper cortices). Pre-
inclusions were noted (Figure 2C) but not included in
the assessment of case classification. The type and dis-
tribution of pathology in the harmonized classification
system was used for FTLD-TDP subtyping [3] as illus-
trated and detailed in Figure 1. All analyses were
performed while blinded to subject details, clinical and
neuropathological diagnosis.
Statistics
The final classification of cases into pathological sub-
types was determined by the most common subtype given
in the present analysis using data from all observers and all
stains (that were performed at the same time), and consid-
eration of the diagnostic pathology observed during case
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over years). The reproducibility of classifying cases into the
three different subtypes (A, B and C) was tested using data
from five independent researchers blind to case details and
κ statistics for multiple raters [25]. For each subtype,
inter-observer percentage agreement was also calculated
[26] for each antibody used. Published guidelines for
interpreting the κ and agreement values were used [27]:
0.00-0.20 = slight agreement, 0.21-0.40 = fair agree-
ment, 0.41-0.60 = moderate agreement, 0.61-0.80 =
substantial agreement, 0.81-1.00 = almost perfect
agreement.
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